Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Press Releases

Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor Conference Call

SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the fourth quarter and the twelve months ended December 31, 2014 on Thursday, March 12, 2015 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).

A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene's senior management team will host a conference call on Thursday, March 12, 2015 at 5:00 p.m. Eastern Daylight Time (2:00 p.m. Pacific Daylight Time) to discuss the results and update investors on the Company's progress.

A live webcast of the call will be available online at www.trovagene.investorroom.com. To access the conference call, please dial (888) 347-6081 (domestic), (412) 902-4285 (international), or (855) 669-9657 (Canada), conference ID# 10061230. To access the telephone replay of the call, dial (877) 344-7529 (domestic), (412) 317-0088 (international), or (855) 669-9658 (Canada), replay ID# 10061230. The replay will be available one hour after the conclusion of the call. The webcast and telephone replay will be archived on the Company's website following the conference. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Contact

Investor Relations


Media Relations

David Moskowitz and Amy Caterina

Investor Relations


Ian Stone

Account Director

Trovagene, Inc.


Canale Communications, Inc.

858-952-7593


619-849-5388

ir@trovagene.com


ian@canalecomm.com

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-schedules-release-of-fourth-quarter-and-year-end-2014-financial-results-and-investor-conference-call-300042381.html

SOURCE Trovagene, Inc.